Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy. The price is a significant premium on the $5.5 bn ...

Celgene aims to boost the effectiveness of its novel drug marizomib for aggressive brain tumour glioblastoma (GBM) by asking patients to wear a special cap. Marketed by Novocure, the Optune ...

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome ...

Celgene has acquired Gloucester Pharmaceuticals for US$340 million upfront and up to $300 million in milestones. Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone ...

Under the deal, Celgene shareholders received $50 in cash plus a tradeable CVR for each share held, with the CVR entitling ...

Celgene (Warren, NJ), a developer of chirally pure drugs, agreed on June 30 to purchase gene-regulation firm Signal Pharmaceuticals (San Diego, CA) for $200 million in an all-stock deal.

Several recent Celgene Corp. patents detail the development of proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety covalently linked to an interleukin-1 ...